FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi

Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other

Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik

Related Stocks: BIIB

FDA clears at-home start dose for Alzheimer's drug Leqembi

FDA clears at-home start dose for Alzheimer's drug Leqembi Phil.Taylor Tue, 14/07/2026 - 08:36

Canada's Drug Agency recommends funding lecanemab for early-stage Alzheimer's disease

Canada's Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer's dis

<![CDATA[FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease]]>

FDA Approves Leqembi: First Drug to Slow Alzheimer's Disease Progression

With the FDA giving the green light to Leqembi, there is renewed hope to millions, promising a potential game-changer in the fight against t